Back to search

Article

Remote monitoring of CAR T-cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA program

2024-02-15

Abstract excerpt

<title>Abstract</title> <p> <bold>Background</bold> CAR T-cells have been approved for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), acute lymphoblastic leukemia (ALL), and multiple myeloma (MM). Although acute toxicities of CAR T-cells are well handled during hospitalization, delayed complications, including cytopenias, i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b9562100-b95c-57f2-a54d-2781312aa65b
DOI
10.21203/rs.3.rs-3937178/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Remote monitoring of CAR T-cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA programDOI 10.21203/rs.3.rs-3937178/v1
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The NetherlandsSemantic proximity
Clinical outcomes of chimeric antigen receptor T cell therapy in 21 patients with Relapse/Refractory Ileocecal Region B cell lymphomaSemantic proximity
Brexucabtagene Autoleucel For Relapsed/Refractory Mantle Cell Lymphoma in Asia: Redefining the Role of Allogeneic Haematopoietic Stem Cell TransplantationSemantic proximity
Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity
Clinical outcomes of chimeric antigen receptor T cell therapy in 21 patients with Relapse/Refractory Ileocecal B cell lymphomaSemantic proximity
Robust CD4 <sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelSemantic proximity
Further modification of the EASIX score through the addition of phosphorous and IL-6 improves prediction of CRS and ICANS after CAR-T therapySemantic proximity
Outcomes of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma by Race: A Multicenter Real-World StudySemantic proximity
Transient adverse events after REGN-CoV2 administration for mild COVID-19 patients and their potential predictive factors: a single center analysisSemantic proximity
The Cancer Treatment Helpline – a retrospective study of the NHS Tayside ExperienceSemantic proximity
Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors: A Systematic Review and Meta-AnalysisSemantic proximity
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational studySemantic proximity
Select a neighboring publication to make it the new centre.